114 related articles for article (PubMed ID: 36017860)
21. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents.
Samatiwat P; Prawan A; Senggunprai L; Kukongviriyapan U; Kukongviriyapan V
Tumour Biol; 2016 Aug; 37(8):11495-507. PubMed ID: 27015836
[TBL] [Abstract][Full Text] [Related]
22. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
23. Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines.
Skowron MA; Niegisch G; Albrecht P; van Koeveringe G; Romano A; Albers P; Schulz WA; Hoffmann MJ
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28767070
[TBL] [Abstract][Full Text] [Related]
24. miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
Yin Y; Liu H; Xu J; Shi D; Zhai L; Liu B; Wang L; Liu G; Qin J
Oncol Rep; 2018 Dec; 40(6):3479-3488. PubMed ID: 30542710
[TBL] [Abstract][Full Text] [Related]
25. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance.
Mirzaei S; Mohammadi AT; Gholami MH; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Makvandi P; Samec M; Liskova A; Kubatka P; Nabavi N; Aref AR; Ashrafizadeh M; Khan H; Najafi M
Pharmacol Res; 2021 May; 167():105575. PubMed ID: 33771701
[TBL] [Abstract][Full Text] [Related]
26. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
27. Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma.
Liu WK; Jiang XY; Zhang ZX
Onkologie; 2010; 33(5):241-5. PubMed ID: 20502058
[TBL] [Abstract][Full Text] [Related]
28. A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells.
Tang YC; Chang HH; Chen HH; Yao JY; Chen YT; Chuang YJ; Chang JY; Kuo CC
J Food Drug Anal; 2021 Dec; 29(4):638-652. PubMed ID: 35649133
[TBL] [Abstract][Full Text] [Related]
29. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.
Zeng H; Zhao X; Tang C
Cancer Chemother Pharmacol; 2021 Aug; 88(2):223-233. PubMed ID: 33907880
[TBL] [Abstract][Full Text] [Related]
31. Targeting RNF8 effectively reverses cisplatin and doxorubicin resistance in endometrial cancer.
Yang B; Ke W; Wan Y; Li T
Biochem Biophys Res Commun; 2021 Mar; 545():89-97. PubMed ID: 33548629
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Suppression of the T-box Subfamily 2 (
Nehme E; Rahal Z; Sinjab A; Khalil A; Chami H; Nemer G; Kadara H
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866410
[TBL] [Abstract][Full Text] [Related]
33. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
34. The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells.
Silva MM; Rocha CRR; Kinker GS; Pelegrini AL; Menck CFM
Sci Rep; 2019 Nov; 9(1):17639. PubMed ID: 31776385
[TBL] [Abstract][Full Text] [Related]
35. MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Li Y; Zhang S; Wang Y; Peng J; Fang F; Yang X
BMC Cancer; 2018 Dec; 18(1):1294. PubMed ID: 30594176
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
37. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
38. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
39. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
40. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
Wang LJ; Wang SG; Deng TX
Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
